The European Commission granted marketing authorization for Ebvallo (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein Barr virus positive post-transplant lymphoproliferative disease who have received at least one prior therapy.
OncoHost, together with its partners Heidelberg University Hospital, European Institute of Oncology and Virgen Macarena University Hospital, announced on May 15 that the parties have been awarded a €2.5 million grant from the EIC Transition Program of Horizon Europe.
